Disruptive Technology Award

Monday, August 5
4:30 – 6 p.m.

AACC’s Disruptive Technology Award recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high quality testing. The award’s 3 finalist teams will present data on their technologies during this special session at the 71st AACC Annual Scientific Meeting.

During the session, a panel of expert judges will evaluate all presented testing solutions based on feasibility and performance. The team with the highest score from the judges will win the 2019 AACC Disruptive Technology Award. The audience will also get a chance to vote for their favorite technology to determine the Audience Choice winner. Learn more about the award details.

Additionally, meeting attendees will be able to learn more about the finalists' and semi-finalists’ technologies by visiting them in AACC’s brand new Innovation Zone, located in the Clinical Lab Expo exhibit hall.



Congratulations to the 3 finalists who will present the following technologies:

Inflammatix logo
The HostDxTM Sepsis test evaluates the patient (“host”) response to better diagnose acute infections and sepsis. The test reveals acute infection or sepsis where pathogens have NOT entered the bloodstream or aren’t detectable, which is the case for most patients. The expression levels of 29 host immune genes are measured and combined by clinically validated advanced proprietary algorithms to inform on the likelihood of a bacterial infection, the separate likelihood of a viral infection, and the infection’s severity (e.g. 30-day mortality risk). The HostDx Sepsis test will be performed on a point-of-care sample-to-answer diagnostic instrument in under 30 minutes.

PixCell_logo new
PixCell's disruptive lab-on-cartridge and artificial intelligence technology offers a paradigm shift in healthcare by simplifying blood tests and making high-end advanced diagnostics accessible at the point of care, thus enabling the widespread early detection of cancer, heart failure, and infection.

The Singlera Genomics ColonES test uses next-generation sequencing-based targeted methylation haplotyping of bisulfite-treated cell-free DNA for early colorectal cancer screening. Singlera Genomics applies methylation haplotype analysis to cell-free DNA for early detection of cancer, by using a highly specific and targeted methylation enrichment method using next-generation sequencing. Combining a genome-wide target screening methodology, patented methylation haplotyping technology and informatics, and an efficient and specific targeted methylation enrichment method called MethylTitan, Singlera’s ColonES assay has been shown to have 97% sensitivity for colorectal cancer (stage I) with a specificity greater than 99%.


A special mention and congratulations to the award semi-finalists.

logo Bacteromic  Purple_Logo_combinati
 Curiosity Diagnostics logo  Newomics logo_tagline

Thank you from AACC to all the applicants who submitted their technology to this competition. We wish you all the best and invite you to apply again in the future.


Please contact conference@aacc.org if you have any questions about AACC's Disruptive Technology Award.

Meet Last Year's Winner

GNA Biosolutions, the winner of AACC’s first Disruptive Technology Award, believes it can speed molecular testing by a factor of 10 for point-of-care diagnostics. Read more.